CytoPherx, Inc., founded in July 2007 and headquartered in Ann Arbor, Michigan, is a venture-backed, clinical stage medical device company addressing inflammation-based diseases and conditions with a proprietary selective cytopheresis system.

The Company’s products are custom, patent-protected configurations of commercially available hollow fiber dialysis filters that are used in a proprietary manner to sequester and deactivate leukocytes in the patient’s blood system. The Company is initially focused on acute renal failure (ARF), end-stage renal disease (ESRD) and acute inflammation induced by cardio pulmonary bypass (CPB) surgery.

Devices not cleared or approved for use in the United States.

For more information please contact CytoPherx, Inc. at 734.272.4772